Interim Results of a Phase II/III Multicenter Randomized Clinical Trial of AVIFAVIR in Hospitalized Patients with COVID-19
ABSTRACT In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 24. März Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ivashchenko, Andrey A. [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2020.07.26.20154724 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018500633 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018500633 | ||
| 003 | DE-627 | ||
| 005 | 20230429095617.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200807s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.07.26.20154724 |2 doi | |
| 035 | |a (DE-627)XBI018500633 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.07.26.20154724 | ||
| 035 | |a (biorXiv)10.1101/2020.07.26.20154724 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Ivashchenko, Andrey A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interim Results of a Phase II/III Multicenter Randomized Clinical Trial of AVIFAVIR in Hospitalized Patients with COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. | ||
| 700 | 1 | |a Dmitriev, Kirill A. |e verfasserin |4 aut | |
| 700 | 1 | |a Vostokova, Natalia V. |e verfasserin |4 aut | |
| 700 | 1 | |a Azarova, Valeria N. |e verfasserin |4 aut | |
| 700 | 1 | |a Blinow, Andrew A. |e verfasserin |4 aut | |
| 700 | 1 | |a Egorova, Alina N. |e verfasserin |4 aut | |
| 700 | 1 | |a Gordeev, Ivan G. |e verfasserin |4 aut | |
| 700 | 1 | |a Ilin, Alexey P. |e verfasserin |4 aut | |
| 700 | 1 | |a Karapetian, Ruben N. |e verfasserin |4 aut | |
| 700 | 1 | |a Kravchenko, Dmitry V. |e verfasserin |4 aut | |
| 700 | 1 | |a Lomakin, Nikita V. |e verfasserin |4 aut | |
| 700 | 1 | |a Merkulova, Elena A. |e verfasserin |4 aut | |
| 700 | 1 | |a Papazova, Natalia A. |e verfasserin |4 aut | |
| 700 | 1 | |a Pavlikova, Elena P. |e verfasserin |4 aut | |
| 700 | 1 | |a Savchuk, Nikolay P. |e verfasserin |4 aut | |
| 700 | 1 | |a Simakina, Elena N. |e verfasserin |4 aut | |
| 700 | 1 | |a Sitdekov, Tagir A. |e verfasserin |4 aut | |
| 700 | 1 | |a Smolyarchuk, Elena A. |e verfasserin |4 aut | |
| 700 | 1 | |a Tikhomolova, Elena G. |e verfasserin |4 aut | |
| 700 | 1 | |a Yakubova, Elena V. |e verfasserin |4 aut | |
| 700 | 1 | |a Ivachtchenko, Alexandre V. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 24. März |
| 773 | 1 | 8 | |g year:2021 |g day:24 |g month:03 |
| 856 | 4 | 0 | |u https://doi.org/10.1093/cid/ciaa1176 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.07.26.20154724 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 24 |c 03 | ||
| 953 | |2 045F |a 570 | ||